# Final Review (Gemini-3-Flash)

**Purpose:** Log the paper's final state after all revisions
**Model:** gemini-3-flash-preview
**Paper:** paper.pdf
**Timestamp:** 2026-02-03T19:46:03.593123
**Route:** Direct Google API + PDF
**Tokens:** 26869 in / 1364 out
**Response SHA256:** e8746ab7a52a1833

---

**Referee Review**

**Title:** State Insulin Copay Cap Laws and Diabetes Mortality: A Difference-in-Differences Analysis  
**Journal:** AEJ: Economic Policy / General Interest Journal

---

### 1. FORMAT CHECK

*   **Length:** The paper is approximately 49 pages, including appendices and references. This exceeds the 25-page requirement for a substantive empirical contribution.
*   **References:** The bibliography is comprehensive, citing essential econometric literature (Callaway & Sant’Anna, Goodman-Bacon, Rambachan & Roth) and health economics foundational work (RAND Experiment).
*   **Prose:** Major sections (Introduction, Conceptual Framework, Methodology, Results, and Discussion) are written in high-quality paragraph form. Bullets are used appropriately for variable definitions and database components.
*   **Section Depth:** Each major section is substantive, typically exceeding 3+ paragraphs.
*   **Figures/Tables:** All figures have clear axes, labels, and self-explanatory notes. Tables include real coefficients and standard errors.

---

### 2. STATISTICAL METHODOLOGY (CRITICAL)

The paper employs a rigorous and state-of-the-art econometric approach.

*   **Standard Errors:** Coefficients in Table 3 and Table 5 include SEs in parentheses.
*   **Significance Testing:** Inference is clearly conducted using p-values and stars.
*   **Confidence Intervals:** 95% CIs are reported for all primary robustness specifications in Table 4 and Table 10.
*   **Sample Sizes:** $N$ is reported for all regressions.
*   **DiD with Staggered Adoption:** The paper correctly avoids simple TWFE as the primary estimator. It uses **Callaway & Sant’Anna (2021)** and **Sun & Abraham (2021)** to account for heterogeneous treatment effects and staggered timing. It further validates the design with a **Goodman-Bacon (2021)** decomposition.
*   **Sensitivity:** The inclusion of **Rambachan & Roth (2023)** HonestDiD analysis is a major strength, addressing potential violations of the parallel trends assumption.

---

### 3. IDENTIFICATION STRATEGY

The identification strategy is highly credible for a policy evaluation.
*   **Parallel Trends:** The author provides an extensive pre-trend analysis (19 years) and an event-study plot (Figure 3) that shows no systematic divergence prior to treatment.
*   **Placebo Tests:** The use of cancer and heart disease mortality as placebo outcomes (Section 6.6) provides strong evidence against selection-on-trends or contemporaneous state-level shocks.
*   **COVID-19:** The paper acknowledges the pandemic as a major confounder and addresses it via controls and by excluding 2020–2021 from the sample, finding robust results.
*   **Limitations:** Section 7.4 provides a candid discussion of the data gap (2018–2019) and outcome dilution.

---

### 4. LITERATURE

The paper is well-positioned. It cites the foundational methodology papers required:
*   Callaway and Sant’Anna (2021)
*   Goodman-Bacon (2021)
*   Sun and Abraham (2021)
*   Rambachan and Roth (2023)

**Suggestions for missing references:**
While the literature review is strong, the paper could benefit from engaging more deeply with the specific "value of a statistical life" (VSL) literature regarding pharmaceutical pricing to frame the "cost" of the null finding.
*   Suggested: *Bresnahan, T. F. (1986). "Measuring the Spillovers from Technical Advance: Mainframe Computers in Financial Services."* (Contextualizing the welfare gains from price drops even if mortality is stagnant).
*   Suggested: *Garthwaite, C. (2012). "The Economic Returns to Pharmaceutical Innovation."*

---

### 5. WRITING QUALITY (CRITICAL)

The writing quality is exceptional for a technical economics paper.
*   **Narrative Flow:** The Introduction (Section 1) successfully hooks the reader by framing insulin as a "public health crisis" and explaining the "gap" in existing literature (proximate outcomes vs. mortality).
*   **Sentence Quality:** The prose is crisp and active. For example: *"The null finding is informative rather than disappointing. It demonstrates that the causal chain... operates over a longer time horizon than currently observable."* (p. 30).
*   **Accessibility:** The paper provides excellent intuition for econometric choices (e.g., explaining why TWFE is biased in the presence of treatment effect heterogeneity).
*   **Magnitudes:** The author provides a "Minimum Detectable Effect" (MDE) calculation (Section 7.2), which is vital for interpreting a null result. This prevents the reader from dismissing the study as simply "underpowered" without context.

---

### 6. CONSTRUCTIVE SUGGESTIONS

*   **Age-Specific Analysis:** As noted in the limitations, the "all-ages" rate includes Medicare beneficiaries. While the author states state-year age-specific data is not publicly available in the "Leading Causes" set, they could potentially use the **CDC WONDER Underlying Cause of Death (Detailed Mortgage)** database to extract 25–64 mortality specifically, even if some cells are suppressed. This would significantly reduce the dilution factor discussed in Section 7.2.
*   **ER Visits:** The paper mentions emergency department visits for DKA in the conclusion. Moving this from a "future direction" to a "supplementary analysis" (if data permits) would provide the "missing link" in the causal chain.

---

### 7. OVERALL ASSESSMENT

This is a high-quality, "clean" empirical paper. While the result is a null, the rigor with which the author explores the **reasons** for the null (dilution, time lags, MDE analysis) makes it a valuable contribution to the literature on pharmaceutical price caps. The methodology is beyond reproach, and the writing is publication-ready for a top-tier journal.

**DECISION: MINOR REVISION** (Primarily to encourage the exploration of age-specific mortality data if at all possible to address the dilution issue).

DECISION: MINOR REVISION